drugset / Trial / NCT06124807
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or overweight. The study will last about 62 weeks.
Timeline
- Start
- 2023-11-17
- Primary completion
- 2025-01-22
- Completion
- 2025-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mazdutide | Protein / enzyme biologic | 6 mg | Subcutaneous |
| Subject | Mazdutide | Protein / enzyme biologic | 10 mg | Subcutaneous |
| Subject | Mazdutide | Protein / enzyme biologic | 16 mg | Subcutaneous |